Welcome to our dedicated page for Exelixis SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
Exelixis, Inc. EVP and CFO Christopher J. Senner reported an open‑market sale of 34,901 shares of common stock at a weighted average price of $50.00 per share. The sale was executed as a standard market transaction.
In a separate non‑market event, 40,892 shares were withheld by Exelixis to cover taxes on vesting of previously granted restricted stock units at $51.10 per share. Following these transactions, Senner directly owns 952,317 shares of Exelixis common stock and indirectly holds 2,723 shares through the company’s 401(k) plan. Footnotes also state that 403,915 additional shares are subject to unvested RSUs and performance-based awards that may be issued upon future vesting.
EXELIXIS, INC. executive Patrick J. Haley, EVP, Commercial, reported a tax-related share withholding tied to vesting of prior equity awards. On the transaction date, the company withheld 33,265 shares of common stock at $51.10 per share to satisfy tax obligations on vested RSUs. Following this non-market disposition, Haley reported ownership of 389,748 shares of Exelixis common stock. This figure includes 356,992 shares that will be issued upon vesting of RSUs and a performance-based restricted stock unit award, plus 646 shares acquired through the Exelixis Employee Stock Purchase Plan.
Exelixis, Inc. SVP and General Counsel Brenda Hefti reported an open-market sale of 6,625 shares of common stock at a weighted average price of $50.21 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on November 19, 2025.
Separately, 6,411 shares were withheld by Exelixis to cover taxes due on the vesting of restricted stock units granted in 2022, 2024, and 2025. After these transactions, she holds 106,762 shares directly and 5,527 shares indirectly through the Exelixis 401(k) Plan.
Her holdings include 106,039 shares that will be issued upon vesting of RSUs and a performance-based restricted stock unit award granted on March 31, 2025, plus 167 shares acquired on April 30, 2026 through the Exelixis 2000 Employee Stock Purchase Plan.
Exelixis EVP Dana Aftab reported routine share activity tied to equity compensation. On the Form 4, 30,578 shares of common stock were withheld by Exelixis at a price of $51.10 per share to cover taxes due upon vesting of previously granted restricted stock units.
After this tax-withholding disposition, Aftab holds 638,192 shares of Exelixis common stock directly, plus 5,835 shares indirectly through the company’s 401(k) plan. Footnotes also note additional unvested RSUs and performance-based stock units that may convert into common shares over time.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice for proposed sales of Common Stock tied to restricted stock vesting under a registered plan. The filing lists proposed sale dates of 05/15/2026 and specific parcel sizes of 9,454, 9,833, 8,748, and 6,866 shares.
The notice records the sales as arising from restricted stock vesting under a registered plan with the issuer identified as the source; brokerage and execution details are not provided in the excerpt.
EXEL affiliate reported a proposed sale of 100,000 shares of Common Stock on Form 144.
The filing shows an aggregate amount of $5,091,190.00, identifies the holder as Michael Morrissey/Morrisey Family Trust, notes the shares were received as a Gift from Affiliate on 11/11/2025, and records 11/15/2020 as an earlier acquisition date. The Form 144 entry lists NASDAQ and the filing date 05/14/2026.
EXELIXIS, INC. director Mary C. Beckerle reported an exercise-and-sell transaction in company stock. She sold 7,712 shares of common stock in an open-market sale at $48.45 per share. She also exercised options to acquire 3,856 shares at an exercise price of $23.24 per share. Following these transactions, she holds 25,236 shares of common stock, including 17,524 shares that will be issued upon vesting of restricted stock units.
EXELIXIS, INC. director Maria C. Freire reported an exercise-and-sale transaction in company stock. On May 7, 2026, she exercised options to acquire 20,634 shares of Common Stock at $19.77 per share, then sold 20,634 shares in an open-market sale at $46.00 per share.
After these transactions, she directly holds 100,819 shares of Common Stock, which include 9,812 shares that will be issued upon vesting of restricted stock units. The option exercised covered 20,634 shares, became fully exercisable on May 23, 2019, and now has no remaining balance.
EXELIXIS, INC. director George Poste reported an open-market sale of 60,000 shares of common stock on May 7, 2026 at a weighted average price of $45.71 per share. The transactions were executed in multiple trades between $45.65 and $45.85 per share.
Following the sale, Poste directly holds 118,832 shares of Exelixis common stock, which includes 9,812 shares that will be issued upon vesting of restricted stock units (RSUs). Each RSU represents the economic equivalent of one share of common stock.